Patterns in the Data

With machine learning, a genomics company is moving into drug development, Technology Review reports.

Deep Genomics, which had been focusing on using its machine-learning tools to search for genetic changes that might be causal for certain diseases, is now setting its sights on developing drugs. According to Tech Review, Deep Genomics will first try its hand at developing drugs for Mendelian disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.